Hear directly from Prashant Warier, our CEO and Co-founder, as he offers his perspective on the latest Series D funding round. Qure.ai, a global healthcare AI leader, recently secured $65 million to fuel its expansion into the US and other markets, invest further in AI technology, and facilitate strategic acquisitions of med-tech companies.
Back
Warier highlights how this investment will propel Qure.ai’s mission to make healthcare more accessible worldwide, particularly in critical areas like TB, lung cancer, and stroke. He reflects on how the company's AI solutions, already deployed across 3,000+ sites in over 90 countries, have proven pivotal in detecting these life-threatening conditions early. With 18 FDA-cleared indications and Class IIb certification in the EU, Qure.ai’s impact is expanding at a global level.
The Series D round brought in new investors, led by Lightspeed and 360 ONE Asset, with participation from Merck Global Health Innovation Fund and Kae Capital, alongside existing backers like Novo Holdings, Health Quad, and TeamFund. Warier discusses the importance of this funding in overcoming healthcare bottlenecks, improving diagnostic accuracy, and enhancing patient care globally, especially in underserved regions.
He emphasizes how AI-driven medical imaging has revolutionized healthcare by alleviating backlogs, boosting diagnostic precision, and overcoming workforce shortages, not only in the US and Europe but also in developing countries. Warier also underlines Qure.ai’s strategic partnerships with major Pharma and MedTech companies like AstraZeneca and Medtronic, which further enhance early diagnosis and timely treatment for critical diseases. The new funding, he adds, marks a pivotal moment for Qure.ai in reaching its goal of benefiting a billion patients worldwide through AI-powered healthcare innovation.
Hear from our Chief Financial Officer, Harsh Vaish
